These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 8212751)

  • 1. [Anticoagulation: assessment of benefits and risks].
    von Knorre GH
    Z Gesamte Inn Med; 1993 Sep; 48(9):453-8. PubMed ID: 8212751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Oral anticoagulation for prevention of thromboembolism in non-rheumatic atrial fibrillation: indications, effectiveness and risk].
    Kottkamp H; Willems S; Hindricks G; Chen X; Haverkamp W; Hasfeld M; Borggrefe M; Breithardt G
    Z Kardiol; 1993 Nov; 82(11):667-73. PubMed ID: 8291287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Anticoagulation in patients with atrial fibrillation].
    Mügge A
    Herz; 1996 Feb; 21(1):28-36. PubMed ID: 8647577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Atrial fibrillation and thromboembolic events prevention. State of the art].
    Matteoli S; Trappolini M; Chillotti FM
    Minerva Cardioangiol; 2001 Feb; 49(1):1-13. PubMed ID: 11279381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Anticoagulation in atrial fibrillation].
    Binggeli C; Brunckhorst CB
    Herz; 2008 Feb; 33(1):13-9. PubMed ID: 18273573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticoagulation with the low-molecular-weight heparin dalteparin (Fragmin) in atrial fibrillation and TEE-guided cardioversion.
    Bechtold H; Gunzenhauser D; Sawitzki H; Fung S; Janssen D
    Z Kardiol; 2003 Jul; 92(7):532-9. PubMed ID: 12883837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bleeding while starting anticoagulation for thromboembolism prophylaxis in elderly patients with atrial fibrillation: from bad to worse.
    Wyse DG
    Circulation; 2007 May; 115(21):2684-6. PubMed ID: 17533193
    [No Abstract]   [Full Text] [Related]  

  • 8. [Inadequate therapies with implantable cardioverter-defibrillators--incidence, etiology, predictive factors and preventive strategies].
    Weber M; Block M; Brunn J; Bänsch D; Böcker D; Hammel D; Gietzen F; Breithardt G
    Z Kardiol; 1996 Nov; 85(11):809-19. PubMed ID: 9064943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Current recommendations for prevention of thromboembolism in patients with heart valve prostheses].
    Gohlke-Bärwolf C
    Z Kardiol; 2001; 90 Suppl 6():112-7. PubMed ID: 11826813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A promising advance in anticoagulant therapy for patients with atrial fibrillation.
    Olsson SB
    Ital Heart J; 2004 May; 5(5):335-9. PubMed ID: 15185895
    [No Abstract]   [Full Text] [Related]  

  • 11. [Study of combined anticoagulant (fluindione)-aspirin therapy in patients with atrial fibrillation at high risk for thromboembolic complications. A randomized trial (FFAACS)].
    Lechat P; Lardoux H; Mallet A; Sanchez P; Derumeaux G; Lecompte T; Maillard L; Mas JL; Mentré F; Pousset F; Lacomblez L; Pisica G; Solbes-Latourette S; Raynaud P; Chaumet-Riffaud P;
    Therapie; 2000; 55(6):681-9. PubMed ID: 11234463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticoagulation and atrial fibrillation.
    Atwood JE; Albers GW
    Herz; 1993 Feb; 18(1):27-38. PubMed ID: 8454250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.
    Stellbrink C; Nixdorff U; Hofmann T; Lehmacher W; Daniel WG; Hanrath P; Geller C; Mügge A; Sehnert W; Schmidt-Lucke C; Schmidt-Lucke JA;
    Circulation; 2004 Mar; 109(8):997-1003. PubMed ID: 14967716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anticoagulation in aged patients with chronic non-rheumatic atrial fibrillation].
    Rodríguez D; Agustí A
    Med Clin (Barc); 1999 Mar; 112(11):436-7. PubMed ID: 10231778
    [No Abstract]   [Full Text] [Related]  

  • 15. Acute anticoagulation adjustment in patients with atrial fibrillation at risk for stroke: approaches, strategies, risks and benefits.
    Olshansky B; Guo H
    Expert Rev Cardiovasc Ther; 2005 Jul; 3(4):571-90. PubMed ID: 16076269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Anticoagulation in atrial fibrillation: not yet settled].
    Montagna R; Asenjo R; Madariaga R
    Rev Med Chil; 1998 Jun; 126(6):689-701. PubMed ID: 9778878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticoagulation for atrial fibrillation: epidemiology informing a difficult clinical decision.
    Singer DE
    Proc Assoc Am Physicians; 1996 Jan; 108(1):29-36. PubMed ID: 8834062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.
    DiMarco JP; Flaker G; Waldo AL; Corley SD; Greene HL; Safford RE; Rosenfeld LE; Mitrani G; Nemeth M;
    Am Heart J; 2005 Apr; 149(4):650-6. PubMed ID: 15990748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [What anticoagulant therapy should be used for what form of atrial fibrillation?].
    Frantz E
    Dtsch Med Wochenschr; 2000 Apr; 125 Suppl 1():S10-1. PubMed ID: 10818997
    [No Abstract]   [Full Text] [Related]  

  • 20. [Prevention of thromboembolism in non-rheumatic atrial fibrillation: an update].
    Pengo V; De Caterina R
    Ital Heart J Suppl; 2001 Sep; 2(9):972-9. PubMed ID: 11675834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.